Tadeu Lima Montagnoli
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Centro de Ciências da Saúde
Unidade:
Instituto de Ciências Biomédicas
Departamento:
Técnico Administrativos/ICB
Formação:
-
Universidade Federal do Rio de Janeiro
Ciências Biológicas (Farmacologia e Química Medicinal) | Doutorado | 2018 - 2023
-
Universidade Federal do Rio de Janeiro
Engenharia Química | Graduação | 2009 - 2018
-
Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro
| Ensino Profissional de nível técnico | 2005 - 2008
Laboratórios:
Nuvens de Palavras:
Artigos:
Nenhum artigo cadastrado
Eventos:
(8.00% eventos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| New sulphonohydrazone ROCK inhibitor improves ventricular function and vascular remodelling in pulmonary hypertension | 2023 | |
| New Agonist Of A2a Adenosine Receptor Improves Cardiac And Vascular Remodeling Induced By Pulmonary Hypertension In Rats | 2023 | |
| Stem cell therapy and activation of adenosine receptor reduce vascular resistance, cardiac dysfunction and remodelling in pulmonary arterial hypertension | 2023 | |
| New acylhydrazone derivatives reduce inflammatory process and cardiac remodeling induced by myocardial infarction | 2023 | |
| Cardiovascular effect of new N-acylhydrazonic derivatives in rats | 2023 | |
| New Rock Inhibitor Improves Pulmonary Vascular Resistance And Right Ventricle Function In Animal Model Of Pulmonary Arterial Hypertension | 2023 | |
| Heart Failure In Menopause: Treatment With Rock Inhibitor And Atorvastatin | 2023 | |
| Evaluation Of Novel A3 Adenosine Receptor Agonist In Hypertension | 2023 | |
| NEW RHO KINASE INHIBITOR ATTENUATES NEUROPATHIC PAIN IN DIABETIC RATS | 2023 | |
| Pharmacological evaluation of a new agonist of adenosine A2a receptor on pulmonary hypertension in rats | 2023 | |
| FASUDIL: IMPROVEMENT OF VENTRICULAR DYSFUNCTION ON ESTROGEN DEPLETION MODEL | 2023 | |
| Novos inibidores de Rho-cinase reduzem disfunção cardíaca e remodelamento vascular em ratos com hipertensão pulmonar | 2022 | |
| New ROCK inhibitor improves cardiovascular function and pulmonary artery remodeling in pulmonary arterial hypertension | 2022 | |
| Activation of adenosine receptor reduces inflammatory process and cardiac remodeling induced by myocardial infarction | 2022 | |
| Reduction of cardiac and vascular remodeling in pulmonary hypertension induced by agonist of A2A adenosine receptor | 2022 | |
| Synthesis and ADME characterization of new sulfonylhydrazones designed as Rho kinase inhibitors for treatment of cardiovascular diseases | 2022 | |
| Activation of adenosine receptors improved cardiac dysfunction induced by myocardial infarction | 2021 | |
| Synthesis of newly substituted isoquinolinesulfonylhydrazones designed as Rho kinase inhibitors for treatment of heart failure and pulmonary hypertension | 2020 | |
| Association of human mesenchymal stem cell and lodenafil in hypoxia-induced pulmonary arterial hypertension | 2020 | |
| Pulmonary hypertension: reduction of vascular and cardiac remodeling by a new inhibitor of p38-alpha MAPK | 2020 | |
| New Rho-kinase inhibitors reduce cardiac dysfunction and vascular remodeling in pulmonary hypertension in rats | 2020 | |
| New DPP-4 inhibitor attenuates metabolic disturbance and improves cardiovascular function in Zucker diabetic fatty fat | 2019 | |
| Pharmacological profile of new adenosine receptor agonist in rats submitted to experimental myocardial infarction | 2019 | |
| Novo inibidor de ROCK reduz disfunção cardíaca e vascular induzida pela hipertensão pulmonar em ratos | 2019 | |
| A novel p38-alpha MAPK inhibitor (LASSBio-1824) reverses SU5416/hypoxia-induced pulmonary arterial hypertension in rats | 2019 | |
| Combination of lodenafil and human menschymal cells therapy reduces cardiac and vascular dysfunction in SU5416/hypoxia-induced pulmonary arterial hypertension in rats | 2019 | |
| Melhora do remodelamento cardíaco induzido pelo infarto agudo do miocárdio pela ativação de receptores de adenosina | 2019 | |
| Agonist of adenosine receptor improves ventricular dysfunction after myocardial infarction via inhibition of cardiac fibroblasts | 10.1161/circ.140.suppl_1.15978 | 2019 |
| New inhibitor of p38-alpha MAPK ameliorates pulmonary hypertension induced by Sugen/hypoxia in rats | 10.1161/circ.140.suppl_1.14909 | 2019 |
| Combination of cholinergic receptor agonist (alpha4-beta2) with cholinesterase inhibitor improves hyperalgesia in chronic pain model | 2019 | |
| Eficácia antinociceptiva da interação de um novo agonista do receptor alfa4beta2 com uma anticolinesterásico central em modelos de dor aguda e crônica | 2019 | |
| Improvement of inflammatory-induced pain and joint damage by novel N-acylhydrazone derivative (LASSBio-1027) in murine models | 2018 | |
| A novel p38-alpha MAPK inhibitor (LASSBio-1824) reverses Sugen/hypoxia-induced pulmonary arterial hypertension in rats | 2018 | |
| New agonist of adenosine receptor (LASSBio-1027) improves cardiac remodeling induced by myocardial infarction | 2018 | |
| Novo agonista do receptor de adenosina (LASSBio-1027) melhora o remodelamento cardíaco após infarto agudo do miocárdio | 2018 | |
| Reduction of pain and joint damage by a novel agonist of adenosine receptor in monoarthritis model | 2018 | |
| Human mesenchymal stem cell therapy reverses Sugen5416/hypoxia-induced pulmonary arterial hypertension in mice | 2018 | |
| A novel p38-alpha MAPK inhibitor (LASSBio-1824) reverses Sugen/hypoxia-induced pulmonary arterial hypertension in rats | 2018 | |
| New ROCK inhibitor reduced vascular dysfunction and cardiac hypertrophy induced by pulmonary hypertension | 2018 | |
| Cardiac remodeling in acute myocardial infarction decreases with new agonist adenosine receptor (LASSBio-1027) | 2018 | |
| A novel p38-alpha MAPK inhibitor reverses Sugen/hypoxia-induced pulmonary arterial hypertension in rats | 10.1161/circ.138.suppl_1.16678 | 2018 |
| Novo agente anti-TNF-alpha melhora edema e hiperalgesia em modelo de monoartrite em camundongos | 2018 | |
| Remodelamento cardíaco no infarto agudo do miocárdio diminui com novo agonista de receptor de adenosina (LASSBIO-1027) | 2018 | |
| Activation of a new estrogen receptor (GPER) ameliorates cardiopulmonary dysfunction in female rats with pulmonary hypertension. | 2017 | |
| Pharmacological evaluation of the agonists of nuclear and G protein coupled estrogen receptors in arterial hypertension associated with estrogen depletion | 2017 | |
| Reversão da hipertensão arterial pulmonar induzida pela monocrotalina em ratos pela lodenafila, inibidor da enzima fosfodiesterase-5 | 2017 | |
| Human mesenchymal stem cell therapy reverses Sugen5416/hypoxia-induced pulmonary arterial hypertension in mice | 2017 | |
| Human mesenchymal stem cell therapy reverses Sugen/hypoxia-induced pulmonary arterial hypertension in mice | 10.1161/circ.136.suppl_1.17314 | 2017 |
| Redução da disfunção endotelial e cardíaca após tratamento com derivado N-acilhidrazônico em ratos espontaneamente hipertensos submetidos ao infarto do miocárdio | 2012 | |
| Correlação da evolução da fibrose com eventos patológicos em biópsias de pacientes transplantados renais | 2009 |